[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 06/20/2025, Immix Biopharma (IMMX) director Jason Hsu filed a Form 4 disclosing a single insider transaction. The company issued Hsu a stock option covering 33,000 shares with a strike price of $2.24 per share. The option vests in twelve equal monthly installments from the grant date and expires on 06/20/2035, conditional on his continued service on the board.

After the award, Hsu reports total beneficial ownership of 4,861,913 common shares, broken down as: 893,000 shares held directly; 3,915,913 shares indirectly through Veritas Liberabit Vos, LLC; and 50,000 shares indirectly through Signature Collection Properties, LLC. No sales or dispositions occurred in this filing.

The incremental 33,000-share option grant represents less than 1 % of Hsu’s existing stake and does not materially alter the company’s capital structure. While the transaction reinforces management-shareholder alignment, its small size suggests limited immediate market impact.

Positive

• Director granted 33,000 options at $2.24, underscoring ongoing commitment and aligning incentives with shareholders.

Negative

• None.

Insights

Securities Analyst

TL;DR: Minor option grant; no shares sold; neutral for valuation.

The filing adds only 33 k options to a pre-existing 4.86 m-share position, implying negligible dilution. Absence of sales minimizes negative signalling risk, but the award size is too small to indicate strong insider conviction. Overall, I view the event as routine compensation with neutral implications for IMMX’s share price.

Corporate Governance Expert

TL;DR: Standard board compensation; alignment intact; governance status unchanged.

The option vests monthly over one year, a conventional structure encouraging continued board engagement. Disclosure of indirect holdings through two LLCs maintains transparency. No red flags arise, yet the action is not large enough to be a positive catalyst. Governance outlook therefore remains unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hsu Jason

(Last) (First) (Middle)

11400 WEST OLYMPIC BLVD.

SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								893,000	D
Common Stock								3,915,913	I	See Footnote(1)
Common Stock								50,000	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.24	06/20/2025		A		33,000		(3)	06/20/2035	Common Stock	33,000	$0.00	33,000	D

Explanation of Responses:

1. Jason Hsu is the Sole Member of VERITAS LIBERABIT VOS, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Hsu disclaims beneficial ownership of the securities held by VERITAS LIBERABIT VOS, LLC, except to the extent of his pecuniary interest therein.

2. Jason Hsu is the Sole Member of Signature Collection Properties, LLC and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Hsu disclaims beneficial ownership of the securities held by Signature Collection Properties, LLC, except to the extent of his pecuniary interest therein.

3. The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.

Remarks:

See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.

	/s/ Ilya Rachman as Attorney-In-Fact for Jason Hsu	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of IMMX does Jason Hsu own after the Form 4 filing?

He reports 4,861,913 shares in total—893,000 directly and 3,968,913 indirectly.

What is the strike price of the newly granted stock option to Jason Hsu?

The exercise price is $2.24 per share.

When will the 33,000-share option granted to Jason Hsu fully vest?

It vests in twelve equal monthly installments beginning 06/20/2025 and will be fully vested by 06/20/2026.

Did Jason Hsu sell any IMMX shares in this filing?

No. The Form 4 discloses no share sales or dispositions.

What is the expiration date of the newly granted option?

The option expires on 06/20/2035.